Avalo Therapeutics (AVTX) Enterprise Value (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Enterprise Value came in at -$57.2 million in Q1 2026, down 92080.65% YoY from N/an in Q1 2025, and up 41.88% on a QoQ basis from -$98.3 million in Q4 2025.
Avalo Therapeutics (AVTX) Enterprise Value (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Enterprise Value data on file, last reported at -$57.2 million in Q1 2026.
- Quarterly Enterprise Value fell 92080.65% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 92080.65% YoY) and the FY2025 annual result came in at -$98.3 million, up 26.91% from the prior year.
- Enterprise Value grew to -$57.2 million in Q1 2026, from -$98.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4000.0 in Q1 2024 to a low of -$134.5 million in Q4 2024.
- A 5-year average of -$37.9 million and a median of -$13.4 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 99.98% — and 2026, when it plunged 92080.65%.
- Tracing AVTX's Enterprise Value over 5 years: stood at -$15000.0 in 2022, then slumped by 49333.33% to -$7.4 million in 2023, then slumped by 1714.51% to -$134.5 million in 2024, then rose by 26.91% to -$98.3 million in 2025, then surged by 41.88% to -$57.2 million in 2026.
- The last three Enterprise Value figures came in at -$57.2 million (Q1 2026), -$98.3 million (Q4 2025), and -$84.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -400.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -400.28 Mn |
| Mar 31, 2026 | -57.15 Mn |
| Dec 31, 2025 | -98.34 Mn |
| Sep 30, 2025 | -84.74 Mn |
| Jun 30, 2025 | -70.99 Mn |
| Mar 31, 2025 | -62,000.00 |
| Dec 31, 2024 | -134.55 Mn |
| Sep 30, 2024 | -81.86 Mn |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | -7.42 Mn |
| Sep 30, 2023 | -10.18 Mn |
| Jun 30, 2023 | -6.31 Mn |
| Mar 31, 2023 | -16.69 Mn |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -53,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -38.47 Mn |
| Dec 31, 2021 | -51,000.00 |
| Sep 30, 2021 | -164,000.00 |
| Jun 30, 2021 | -40.44 Mn |